Standard
Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021. / Hallgreen, Christine; Mollebaek, Mathias; Corap, Ertugrul.
In:
Pharmacoepidemiology and Drug Safety, Vol. 31, No. S2, 2022, p. 266-267.
Research output: Contribution to journal › Conference abstract in journal › Research › peer-review
Harvard
Hallgreen, C, Mollebaek, M & Corap, E 2022, 'Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021', Pharmacoepidemiology and Drug Safety, vol. 31, no. S2, pp. 266-267.
APA
Hallgreen, C., Mollebaek, M., & Corap, E. (2022). Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021. Pharmacoepidemiology and Drug Safety, 31(S2), 266-267.
Vancouver
Hallgreen C, Mollebaek M, Corap E. Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021. Pharmacoepidemiology and Drug Safety. 2022;31(S2):266-267.
Author
Hallgreen, Christine ; Mollebaek, Mathias ; Corap, Ertugrul. / Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021. In: Pharmacoepidemiology and Drug Safety. 2022 ; Vol. 31, No. S2. pp. 266-267.
Bibtex
@article{baf93e8d65284063a467fa924ccef95d,
title = "Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021",
author = "Christine Hallgreen and Mathias Mollebaek and Ertugrul Corap",
year = "2022",
language = "English",
volume = "31",
pages = "266--267",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "JohnWiley & Sons Ltd",
number = "S2",
note = "38th International Conference on Pharmacoepidemiology : Advancing Pharmacoepidemiology and Real-World Evidence for the Global Community ; Conference date: 26-08-2022 Through 28-08-2022",
}
RIS
TY - ABST
T1 - Marketing authorization pathways and clinical evidence supporting approval of orphan medicinal products in EU between January 2015 and October 2021
AU - Hallgreen, Christine
AU - Mollebaek, Mathias
AU - Corap, Ertugrul
N1 - Conference code: 38
PY - 2022
Y1 - 2022
M3 - Conference abstract in journal
VL - 31
SP - 266
EP - 267
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
SN - 1053-8569
IS - S2
T2 - 38th International Conference on Pharmacoepidemiology
Y2 - 26 August 2022 through 28 August 2022
ER -
